Deerland Probiotics and Enzymes has announced that it has received a GRAS (generally recognized as safe) no-objection letter for FDA for its Bacillus subtilis DE111 branded probiotic.
Photo © Shutterstock.com/AlexLMX
Deerland Probiotics and Enzymes (Kennesaw, GA) has announced that it has received a GRAS (generally recognized as safe) no-objection letter for FDA for its Bacillus subtilis DE111 branded probiotic. The letter was sent in response to a GRAS self-affirmation dossier submitted by Deerland and means that FDA does not question the basis of the GRAS self-affirmation, following a review of the scientific data.
“We are excited to receive the FDA’s no objection letter for DE111,” said Scott Ravech, CEO of Deerland, in a press release. “It highlights the extensive research, including the clinical trials that have been conducted by our team, and we are proud of this accomplishment.”
In addition to this, DE111 has received non-novel food status in both Canada and Australia, and has been approved as a natural health product ingredient by Health Canada.
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
Recent study compares the effectiveness of two probiotic products on colicky infants
October 31st 2024The study compared AB-Biotics and Kaneka Probiotics’ probiotic formulation of Bifidobacterium longum KABP®-042 and Pediococcus pentosaceus KABP®-041 to Lactobacillus reuteri DSM17938 (LR) from Biogaia.